黄嘌呤氧化还原酶表达对鼻咽癌预后的影响  

Expression of xanthine oxidoreductase and its value in prognosis of patients with nasopharyngeal carcinoma

作　　者：杨见明[1] 陶冶[1] 邓雪飞[2] 

机构地区：[1]安徽医科大学第二附属医院耳鼻喉-头颈外科,合肥230601 [2]安徽医科大学人体解剖学教研室,合肥230032

出　　处：《安徽医科大学学报》2013年第5期496-498,共3页Acta Universitatis Medicinalis Anhui

基　　金：安徽省教育厅自然科学基金(编号:KJ2012Z147)

摘　　要：目的探讨黄嘌呤氧化还原酶(XOR)在鼻咽癌患者中的表达情况,并探讨其对患者预后的影响。方法采用免疫组化法检测90例鼻咽癌患者活检标本的XOR表达情况,并分析其与预后之间的关系。结果鼻咽癌组织XOR阳性表达率为52.2%,在不同病理类型间表达差异无统计学意义。XOR表达TNM分期间存在密切关系。XOR阳性表达患者5年生存率为42.6%,阴性表达者为65.2%,两者比较差异有统计学意义(P<0.05)。结论 XOR可以作为评价鼻咽癌患者预后的参考依据之一。Objective To investigate the expression of xanthine oxidoreductase （XOR） and its value in prognosisof patients with nasopharyngeal carcinoma. Methods Immunohistochemical staining was performed on the biopsy specimen from 90 patients with nasopharyngeal carcinoma. The prognostic value of the XOR immunostaing was evaluated. Results Positive XOR expression was observed in 52. 2% of cases, and there was no signicant difference between pathological manifestations of cancer. The expression of XOR was related to tumor TNM stage. The cumulative 5-years survival rate in patients with positive XOR expression was 42. 6%, compared with 65.2% in those with negatice expression. Conclusion Expression of XOR may be a new prognostic marker for patients with nasopharyngeal carcinoma.

关 键 词：鼻咽癌 黄嘌呤氧化酶 预后 

分 类 号：R766.3[医药卫生—耳鼻咽喉科]